CRS medical as official sales partner of HemoClear in Germany

Since this year, CRS medical has been the official sales partner of HemoClear in Germany and thus distributes the first microfiltration solution for autologous blood transfusions. At the beginning of March, CRS medical and HemoClear B.V. attended the Ludwigshafen Transfusion Talks organised by IAKH e.V. to present HemoClear's autologous blood transfusion procedure in Germany for the first time. HemoClear offers a non-machine alternative to make autologous blood transfusions in hospitals more accessible.

Every year, 100 million blood transfusions with donor blood take place worldwide. Despite their wide applicability, donor blood transfusions are still associated with high overall costs and health risks that lead to medical complications, prolonged recovery or increased mortality. In order to minimise the use of donor blood, many hospitals rely on autologous blood transfusions. This procedure preserves valuable blood cells and "washes out" harmful impurities. HemoClear is designed for the purification and reinfusion of autologous blood and is the first ready-to-use solution for cell recovery. The procedure produces safe and high-quality autologous platelet-rich red blood cells from the patient's blood. HemoClear offers an ideal alternative to mechanical blood transfusion, particularly in the fields of general, cardiovascular, orthopaedic, vascular, plastic/reconstructive, obstetric/gynaecological and neurosurgical surgery as well as in post-operative treatments.

HemoClear enables a cost-effective blood transfusion procedure that can be carried out entirely at the patient's bedside.

The use of HemoClear offers a number of advantages. Patient safety is improved in autologous blood therapy, as possible side effects of foreign blood can be excluded. Furthermore, no electricity is required for transfusion, as the multi-layer module enables excellent filtration by gravity alone. Another advantage is that the cost-effective, simple, sterile and closed filtration procedure takes only 30 minutes and can be performed entirely at the bedside, meaning that it can be carried out by any member of staff in a medical facility.
 

CRS medical as official sales partner in Germany

CRS medical has many years of experience and extensive knowledge in the medical technology sector and has developed into a dynamic and efficient medium-sized company since 2004. Since the beginning of this year, CRS medical has been HemoClear's first and official sales partner in Germany and is enthusiastic about HemoClear's autologous microfiltration process. HemoClear is a company from the Netherlands and the process is already being used in several other countries such as Switzerland. Dr Patrick Uhr, Director Data & Products at CRS medical, summarises the partnership with HemoClear as follows: "We are delighted to be HemoClear's official distribution partner in Germany and to be able to bring a unique product to German hospitals. By using HemoClear, hospitals will be able to rethink surgical plans and make them easier to plan. At the same time, the autologous microfiltration process will make blood transfusion considerably easier."

You can find more information about the product at www.hemoclear.de.